Detalhe da pesquisa
1.
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.
Invest New Drugs;
40(1): 81-90, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34417914
2.
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Blood;
115(3): 475-80, 2010 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965689